TurkuFinland’s University of Turku built the first reliable lab model of BAP1-deficient melanoma.
BAP1-deficient melanoma resists every immunotherapy once metastasized; without a lab model, new therapies could not be tested.
The model lets researchers probe why these tumors evade immune response, a prerequisite for any treatment.
Sources: Phys.org